Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ADBRY safely and effectively. See full prescribing information for ADBRY. ADBRY® (tralokinumab-ldrm) injection, for subcutaneous use Initial U.S. Approval: 2021
Medication labelWhy this: Advisory · dailymed-prescription
ADBRY is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids.
- generic_name
- tralokinumab-ldrm
- product_names
- tralokinumab-ldrm
- ndc
- 50222-346, 50222-350, 50222-346-01, 50222-346-02, 50222-346-22, 50222-346-04, 50222-346-91, 50222-346-92, 50222-350-00, 50222-350-01, 50222-350-02, 50222-350-90, 50222-350-91
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en